Back to discover
Drug
Halothane
In clinical developmentClassGABA-A receptor; anion channel positive allosteric modulatorEmerging researchIn clinical testing
Also known as Alotano, Fluothane, Halotano, 1,1,1-trifluoro-2-bromo-2-chloroethane+5 more
Alotano, Fluothane, Halotano, 1,1,1-trifluoro-2-bromo-2-chloroethane, 1,1,1-trifluoro-2-chloro-2-bromoethane, 1-bromo-1-chloro-2,2,2-trifluoroethane, 2,2,2-trifluoro-1-chloro-1-bromoethane, 2-bromo-2-chloro-1,1,1-trifluoroethane, Halothanum.
1
Research papers
23
Protein targets
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this drug.
Clinical trial2009-12-01Completed · ClinicalTrials.gov
Research1995-01-01The Journal of neuroscience : the official journal of the Society for Neuroscience
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Canonical name
Halothane
Aliases & brands
AlotanoFluothaneHalotano1,1,1-trifluoro-2-bromo-2-chloroethane1,1,1-trifluoro-2-chloro-2-bromoethane1-bromo-1-chloro-2,2,2-trifluoroethane2,2,2-trifluoro-1-chloro-1-bromoethane2-bromo-2-chloro-1,1,1-trifluoroethaneHalothanum
RxNorm CUI
5095
ChEMBL ID
CHEMBL931
ATC codes
N01AB01
UNII
UQT9G45D1P
Primary mechanism
GABA-A receptor; anion channel positive allosteric modulator
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Gamma-aminobutyric acid receptor subunit alpha-1
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRA1 · P14867
Gamma-aminobutyric acid receptor subunit beta-2
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRB2 · P47870
Gamma-aminobutyric acid receptor subunit gamma-2
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRG2 · P18507
Gamma-aminobutyric acid receptor subunit beta-3
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRB3 · P28472
Gamma-aminobutyric acid receptor subunit alpha-4
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRA4 · P48169
Gamma-aminobutyric acid receptor subunit gamma-3
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRG3 · Q99928
Gamma-aminobutyric acid receptor subunit theta
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRQ · Q9UN88
Gamma-aminobutyric acid receptor subunit alpha-3
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRA3 · P34903
Gamma-aminobutyric acid receptor subunit pi
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRP · O00591
Gamma-aminobutyric acid receptor subunit delta
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRD · O14764
Gamma-aminobutyric acid receptor subunit gamma-1
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRG1 · Q8N1C3
Gamma-aminobutyric acid receptor subunit beta-1
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRB1 · P18505
Gamma-aminobutyric acid receptor subunit epsilon
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRE · P78334
Gamma-aminobutyric acid receptor subunit alpha-2
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRA2 · P47869
Gamma-aminobutyric acid receptor subunit alpha-5
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRA5 · P31644
Gamma-aminobutyric acid receptor subunit alpha-6
POSITIVE ALLOSTERIC MODULATORGABA-A receptor; anion channel positive allosteric modulatorGABRA6 · Q16445
Glycine receptor subunit alpha-1
POSITIVE MODULATORGlycine receptor (alpha-1/beta) positive modulatorGLRA1 · P23415
Glycine receptor subunit beta
POSITIVE MODULATORGlycine receptor (alpha-1/beta) positive modulatorGLRB · P48167
Potassium channel subfamily K member 10
OPENERPotassium channel subfamily K member 10 openerKCNK10 · P57789
Potassium channel subfamily K member 18
OPENERPotassium channel subfamily K member 18 openerKCNK18 · Q7Z418
Potassium channel subfamily K member 3
OPENERPotassium channel subfamily K member 3 openerKCNK3 · O14649
Potassium channel subfamily K member 9
OPENERPotassium channel subfamily K member 9 openerKCNK9 · Q9NPC2
Potassium channel subfamily K member 2
OPENERPotassium channel subfamily K member 2 openerKCNK2 · O95069
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY1
registered trials across all phases
LATEST COMPLETION 2009
1
Late-stage (III+)
1
Completed
PHASE DISTRIBUTIONn = 1
Phase N / A1
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Most influential
Journals, researchers & institutions
Top journals
- The Journal of neuroscience : the official journal of the Society for Neuroscience1
Leading researchers
- Bragin A1
- Buzsáki G1
- Jandó G1
- Nádasdy Z1
- Sik A1
- Szabó I1
- Ylinen A1
Leading institutions
free-text, unnormalised
- Center for Molecular and Behavioral Neuroscience1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
References & data sources
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials